This blog highlights the critical role of ovarian cancer clinical trials in accelerating access to new therapies and enhancing scientific understanding. At Lambda Therapeutic Research & Novum Pharmaceutical Research Services, we work closely with global pharmaceutical and biotech partners to conduct high-quality clinical trials aimed at improving outcomes for individuals affected by ovarian cancer.
World Ovarian Cancer Day
Observed on May 8, World Ovarian Cancer Day brings attention to one of the most challenging and under-recognized forms of cancer affecting women. Globally, more than 300,000 women are diagnosed with ovarian cancer each year, and it remains the eighth leading cause of cancer-related deaths among women. Often diagnosed at a late stage due to subtle symptoms and limited early detection tools, the five-year survival rate for advanced ovarian cancer remains significantly lower than for many other cancers. However, with ongoing research and clinical development, there is a growing pipeline of innovative therapies designed to improve survival and quality of life for patients.
A Closer Look at Ovarian Cancer Clinical Trials
Clinical trials are the cornerstone of progress in ovarian cancer treatment, enabling the development of novel therapies and refining existing ones. These studies provide patients with early access to groundbreaking treatments, often years before they become widely available, while offering researchers critical insights into their safety and efficacy.
At Lambda & Novum, we are dedicated to advancing ovarian cancer care through partnerships with global pharmaceutical and biotech innovators. Clinical trials are more than scientific endeavors—they are about hope, resilience, and collaboration among patients, families, caregivers, and researchers. Every trial brings us closer to more effective, personalized treatments, and we are honored to contribute to this mission.
Oncology Excellence: A Proven Track Record
At Lambda & Novum, our commitment to advancing cancer treatment is reflected in our extensive experience in oncology clinical trials. With a strong portfolio that includes over 275 clinical trials spanning 15+ therapeutic areas, oncology remains a cornerstone of our expertise.
68
Oncology Trials
6000+
Patients
900+
Global Sites
Lambda has established a solid track record in ovarian cancer clinical trials, conducting 13 studies. Our experience extends enrolling over 700 patients at 150+ sites, reflecting our ability to manage large, complex trials efficiently while maintaining the highest standards of patient care and data integrity.
Our end-to-end capabilities—ranging from medical imaging to pharmacovigilance, biostatistics, and bioanalytical services—enable us to deliver comprehensive solutions for our clients. By ensuring high standards of quality and regulatory compliance, we consistently achieve robust, reliable trial results. Our successful regulatory submissions to the USFDA, EMA, and ANVISA underscore our deep understanding of global regulatory frameworks and our proficiency in navigating the complexities of the approval process. We also have extensive experience in biosimilar development.
Optimizing Ovarian Cancer Clinical Trials:
Strategic Site Selection
The success of ovarian cancer trials hinges on selecting sites with experienced investigators and staff specialized in gynecologic oncology. Our rigorous site selection process ensures high-quality data collection and a supportive experience for participants.
Streamlining Recruitment & Retention
We prioritize patient-centric approaches, employing care coordinators to address barriers and enhance participant support. These efforts improve retention, streamline recruitment, and foster better outcomes and data quality.
Innovative Trial Protocols
Our trial protocols are designed with patients in mind, incorporating the latest scientific advancements and tailored to the unique needs of ovarian cancer patients. These innovative, patient-friendly designs optimize outcomes and ensure efficient data collection.
Transform Your Oncology Trials with Our Proven Expertise
Explore Our Success Stories:
Leverage Lambda & Novum’s extensive experience & proven track record to accelerate your Oncology clinical trials. Get in touch with our team of experts.
About Lambda
Lambda & Novum delivers comprehensive, end-to-end clinical research services to the innovator, biotech, and generic pharmaceutical industries worldwide. With a strong global presence in India, the USA, Canada, the UK, Spain and Poland, we bring specialized expertise to every project. Our focus on secure IT infrastructure and automation ensures timely project delivery and strict adherence to international regulatory standards. Lambda’s exemplary regulatory track record includes over 60 successful inspections and audits by esteemed authorities, including the USFDA, EMEA, MHRA, EU member states, and other global regulatory bodies, in the past five years.
Lambda’s commitment to excellence has garnered significant recognition, including the ‘Best Indian CRO’ award from Frost & Sullivan (USA) and the ‘Great Indian Workplace’ title from UBS Transformance. Recent accolades include the ‘Regulatory Excellence’ Award at the CPhI Pharma Awards 2023 and the ‘Industry Partner of the Year’ Award at the Global Generics & Biosimilar Awards 2023.
References:
- https://worldovariancancercoalition.org/
